Clinical trial
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With…
NCT00089895 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00089895 |
|---|---|
| Title | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) |
| Official title | Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) |
| Lead sponsor | Organon and Co, Industry |
| Collaborators | Duke Clinical Research Institute |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myocardial Ischemia, Acute Coronary Syndrome |
| Intervention type | Drug |
| Interventions | Eptifibatide (Integrilin), Placebo |
| Enrollment | 9,406 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Aug 19, 2004 |
| Last update posted | May 17, 2024 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: